Terns Pharma Q2 net loss $17.9M; positive Phase 2a NASH data for TERN-501

Terns Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.56

Net loss of $17.9M ($0.25 per share) vs $13.9M a year ago; R&D spend $14.2M.
Cash $285.6M, expected to fund operations into 2026.
Positive Phase 2a DUET trial: TERN-501 met all endpoints in NASH; 45% mean liver fat reduction at 6mg.
TERN-701 Phase 1 for CML and TERN-601 Phase 1 for obesity both on track to start H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Terns Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.9 million for the quarter ended June 30, 2023.

Period: the three and six months ended June 30, 2023
Net income: Net loss was $17.9 million for the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.